Do you feel that DRE is still a relevant tool in the management of prostate cancer? Take our latest poll and let us know.
Hormone therapy plus current treatments improves survival in prostate cancer
March 23rd 2023Darolutamide increased overall survival compared to placebo in the overall patient population and patients with high-volume, high-risk mHSPC as well as in patients with low-risk metastatic hormone-sensitive prostate cancer.
2 Clarke Drive
Cranbury, NJ 08512